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Background. The complex interplay between B-cell lymphoma 2 (Bcl-2) family proteins constitutes a crucial checkpoint in
apoptosis. Its detailed molecular mechanism remains controversial. Our former modeling studies have selected the ‘Direct
Activation Model’ as a better explanation for experimental observations. In this paper, we continue to extend this model by
adding interactions according to updating experimental findings. Methodology/Principal Findings. Through mathematical
simulation we found bistability, a kind of switch, can arise from a positive (double negative) feedback in the Bcl-2 interaction
network established by anti-apoptotic group of Bcl-2 family proteins. Moreover, Bax/Bak auto-activation as an independent
positive feedback can enforce the bistability, and make it more robust to parameter variations. By ensemble stochastic
modeling, we also elucidated how intrinsic noise can change ultrasensitive switches into gradual responses. Our modeling
result agrees well with recent experimental data where bimodal Bax activation distributions in cell population were found.
Conclusions/Significance. Along with the growing experimental evidences, our studies successfully elucidate the switch
mechanism embedded in the Bcl-2 interaction network and provide insights into pharmacological manipulation of Bcl-2
apoptotic switch as further cancer therapies.
Citation: Cui J, Chen C, Lu H, Sun T, Shen P (2008) Two Independent Positive Feedbacks and Bistability in the Bcl-2 Apoptotic Switch. PLoS ONE 3(1):
e1469. doi:10.1371/journal.pone.0001469
INTRODUCTION
Apoptosis is a highly regulated cell suicide program in response to
cell stress, damage or conflicting division signals [1,2]. Once
decision is made, the demise of cell is all-or-none, irreversible
[3,4]. Mitochondria play a central role in apoptosis through
sensing incoming cytotoxic signals and responding by mitochon-
drial outer membrane permeabilization (MOMP). MOMP is
considered as the ‘point of no return’ of mitochondria-dependent
cell death [5]. Once MOMP has occurred, pro-apoptogenic
factors such as cytochrome c, Smac/DIABLO, and Omi/Htra 2,
are released from intermembrane space (IMS) into cytosol where
they initiate multiple cell death pathways irreversibly [6].
It has been widely embraced that the intricate interplay between
threegroupsoftheBcl-2familyproteinsdeterminesthecommitment
of MOMP and subsequent apoptosis [5]. The group of BH-3-only
proteins (include Bim, Bad, Bid, Bik, Bmf, Puma, Noxa and Hrk)
serve as upstream sentinels that selectively respond to specific,
proximal death signals by increasing expressions and/or post-
translational regulations. Somehow they activate the group of
multidomain proteins (include Bax and Bak), which are considered
the critical mediators of apoptosis. Both in vivo and in vitro
experiments proved that activated Bax/Bak can effectively cause
MOMP by forming oligomerized pores (MAC, mitochondrial
apoptosis channel) on mitochondrial outer membrane (MOM) [7].
Another anti-apoptotic group (include Bcl-2, Bcl-xL, Bcl-W, Mcl-1
andA1)hastheoppositeeffectdespitethattheyshareasimilarthree-
dimensional structure with the multidomain group.
Although growing evidence demonstrates Bcl-2 family functions
as an upstream life/death switch [8,9], detailed molecular
mechanism of the so-called ‘Bcl-2 apoptotic switch’ remains
controversial. Whether Bax/Bak is activated directly or indirectly
is a central question. A widely accepted model proposes that the
select BH-3-only proteins termed ‘activators’(tBid, Bim and Puma) is
sufficient to enable a conformational change and pore formation of
Bax/Bak in a ‘hit and run’ manner (Fig. 1A). Other BH-3-only
proteins termed ‘enabler’ (also called de-repressor or sensitizer) can
displace the activators from anti-apoptotic proteins [10]. Recently
Kim and his coworkers provided compelling evidence to supportthis
Direct Activation Model [11]. Another scenario supported by Willis
et al. is that anti-apoptotic proteins inhibit apoptosis by sequestering
Bax/Bak (Fig. 1B) [12,13]. All BH-3-only proteins activate Bax/Bak
indirectly by binding and inactivating their specific anti-apoptotic
relatives. Nevertheless, this Indirect Activation Model is based on a
hypothesis that Bax/Bak alone can spontaneously undergo confor-
mational change and oligomerize without external activation steps,
which still lacks experimental confirmation. Also, our previous
modeling studies suggest that the Direct Activation Model is more
plausible to explain ultrasensitive responses as well as other salient
features of the Bcl-2 apoptotic switch in contrast to the Indirect
Activation Model [14].
Now, quickly accumulated experimental evidence in this field
can help update our understandings for the regulation of Bcl-2
network. As reviewed by Galonek and Hardwick [10], it is evident
that anti-apoptotics can bind directly with activated form of Bax/
Bak, however the interaction between anti-apoptotics and non-
activated Bax/Bak remains suspectable. This fact criticized the
Indirect Activation Model in which non-activated Bax/Bak-anti-
apoptotics interaction is essential. In addition, Dlugosz et al.
proved that Bcl-2, one of the major anti-apoptotics integrated in
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oligomerization [15]. Later, Peng et al. suggested that this
conformational change of Bcl-2 can only be induced by either
tBid (one of the BH-3 only proteins), or activated Bax upon
interaction, but not non-activated Bax [16]. Their findings further
emphasized the importance of activated Bax-anti-apoptotics
interaction. Another issue concerns Bax/Bak auto-activation.
Tan et al. provided solid evidence that activated Bax can directly
induce a conformational change in non-activated Bax, and anti-
apoptotics can prevent Bax auto-activation through binding
activated Bax [17]. Similar observations have also been reported
in Bak [18]. Obviously, these new interactions can significantly
influence the dynamical pattern of the models we discussed before.
In this study, we extended the Direct Activation Model by
incorporating these newly emerged experimental findings. We
mainly focused on their influence on the dynamic patterns in the
extending models. Our analysis demonstrates that two indepen-
dent positive feedback loops in the Bcl-2 network contribute to an
inherent switch to govern apoptosis decision. Bistability can arise
from a positive (double negative) feedback provided by the
interaction between anti-apoptotics and activated Bax/Bak.
Moreover, Bax/Bak auto-activation as another positive feedback
can enforce this switch and make it more robust with respect to
parameter variations. We also use ensemble stochastic modeling to
elucidate the influence of intrinsic noise on this bistable switch.
Our result is well in accord with certain experimental data of flow-
cytometry analysis, where bimodal Bax activation distributions in
cell population are reported. In all, our studies successfully extend
our understanding of the switch mechanism beyond the apoptosis
decision and provide insights into pharmacological manipulation
of Bcl-2 family members as further cancer therapies.
MATERIALS AND METHODS
Model Description
We constructed our models of Bcl-2 apoptotic switch mainly based
on the previously described Direct Model (Fig. 1A) [14]. To
reduce the complexity of the network without sacrificing
fundamental components of the network, we group Bcl-2 family
members into four distinct categories: Bax, Bcl2, Activator, and
Enabler, representing multidomain pro-apoptotic member, anti-
apoptotic members, Activators, and Enablers respectively. Two
newly discovered mechanisms are incorporated by extending our
models. Thus we obtain 3 models with increasing mechanistic
details for further simulation and analysis (Fig. 1A, C and D).
Many pro-death signals initiate apoptosis by regulating the
expression of both anti- and pro-apoptotic Bcl-2 proteins [19].
Pro-apoptotic signals can also control apoptosis by affecting
degradation rate of apoptosis related proteins, such as Bax [20]. So
in this paper we considered the production and degradation rate of
diverse Bcl-2 family members instead of cytotoxic stress as model
inputs. In addition, increasing evidence supports that activated
Bax/Bak is the major component of the cytochrome c release
channel MAC [21]. Therefore, in our simulations the percentage
of activated Bax/Bak is used to evaluate the degree of apoptosis.
Computational modeling
Here we bring forward a set of models realizing mass action
kinetics implemented as ODEs, which is based on the outline of
the Direct Model, Direct Model I and Direct Model II as shown in
Fig. 1. For each model, the state of a cell is described by the
concentrations of all relevant molecules (c1,c 2 …c n). The reaction
rates are dependent on these concentrations and on biochemical
parameters (k1,k 2 …k m) such as binding constants and
dissociation constants. To describe the temporal behavior, a set
of ordinary differential equations is generated in terms of the
following general equation:
dca=dt~
X
vab:Jb
where dca/dt represents the concentration changing rate of
molecule a. Jb denotes the rate of reaction b, and vab denotes the
stoichiometric matrix linking the reaction rates of Jb with the
affected molecule a. Here the reaction scheme, kinetic equations as
well as model parameters of the Direct Model II are represented in
Table 1, Table 2 and Table 3, respectively. And we can get the
Direct Model and the Direct Model I by setting related reaction
rates to 0 based on the Direct Model II (Direct Model:
J2=J 4=J 8=J 9=J AcBaxBcl2=0, see Table S1 and S2 in the
Figure 1. Schematic representation of the models of the Bcl-2 apoptotic switch. (A) The Direct Model. (B) The Indirect Model. (C) The Direct Model I,
considering Activated Bax/Bak-anti-apoptotics interaction. (D) The Direct Model II, considering Bax/Bak auto-activation. Abbreviations used: Ena
(Enabler), Act (Activator), Bcl2 (Anti-apoptotics), InBax (No-activated Bax/Bak), AcBax (Activated Bax/Bak), MAC (Bax oligomer, Mitochondrial
Apoptosis Channel), BH-3 (BH-3 only proteins). Arrows represent material flow and catalyzed reaction. Black lines terminated by a bar denote
interaction and inhibition.
doi:10.1371/journal.pone.0001469.g001
Bistable Bcl2 Apoptotic Switch
PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1469supplementary material; Direct Model I: J9=0, see Table S3 and
S4 in the supplementary material). ODE23s routine was used for
deterministic modeling, while explicit tau-leap method was used
for stochastic modeling (The Mathworks, Natick, MA). The
bifurcation analysis was done in XPPAUT (Version 5.91).
Parametric robustness analysis of bistability
Similar to [22], all parameters are varied +/220% from its default
value to generate 2000 random parameter sets by using Latin
Hypercube Sampling. Since we still know little about the
distributions of parameter values for real biological systems, we
used uniform probability distribution for each parameter in this
paper. For all the in silico simulations, the percentage of existence
of bistability was monitored. The generation of Latin hypercubes
and the determination of bistability are implemented in Matlab.
For each set of kinetic parameters, we search for the existence of a
bistability by the ‘‘coming up and going down’’ method described
previously [23].
RESULTS
Anti-apoptotics Establish an Positive Feedback
Which Brings Bistability
A Bax-activation module has been identified as a bistable switch in
our previous work without considering protein production and
degradation [23]. However, protein production and degradation
have been reported of great importance in apoptosis regulation
[19,20]. Here we continue to investigate whether bistability can
originate from interactions of Bcl-2 family proteins in a model
including protein synthesis and degradation. We first use the
production rate of Activator as the apoptotic stimuli. Our results
suggest that anti-apoptotics can establish a positive (double
negative) feedback and bring bistability to the model.
Wepresentedtwomodelsofincreasingcomplexitytodemonstrate
how bistable behaviors of Bax activation emerge from the intricate
Table 1. Chemical reaction network scheme of the Direct Model II.
a
..................................................................................................................................................
No. Reactions Description k+ k2
1 InBax+ActRAcBax+Act Act-mediated InBax activation k1 -
2 AcBax+Bcl2«AcBaxBcl2 AcBax-Bcl2 dimerization and dissociation k2 k3
3A c t +Bcl2«ActBcl2 Act-Bcl2 dimerization and dissociation k4 k5
4 AcBax+ActBcl2«AcBaxBcl2+Act Displacement between AcBax and Act k6 k7
5 AcBaxRInBax AcBax inactivation k8 -
6E n a +Bcl2«EnaBcl2 Ena-Bcl2 dimerization and dissociation k9 k10
7A c t +EnaBcl2«ActBcl2+Ena Displacement between Act and Ena k12 k11
8 AcBax+EnaBcl2«AcBaxBcl2+Ena Displacement between AcBax and Ena k14 k13
9 InBax+AcBaxRMAC Bax auto-activation and dimerization k15 -
10 2AcBax«MAC AcBax dimerization and dissociation k16 k17
11 InBax«W InBax degradation and production p1 u1
12 AcBaxRW AcBax degradation - u2
13 Act«W Act degradation and production p2 u3
14 Bcl2«W Bcl2 degradation and production p3 u4
15 ActBcl2RW ActBcl2 degradation - u5
16 AcBaxBcl2RW AcBaxBcl2 degradation - u6
17 Ena«W Ena degradation and production p4 u7
18 EnaBcl2RW EnaBcl2 degradation - u8
19 MACRW MAC degradation - u9
aAbbreviations used: InBax (Inactive Bax/Bak), Act (Activator), AcBax (Activated Bax/Bak), Bcl2 (Anti-apoptotics), AcBaxBcl2 (Activated Bax/Bak-Bcl2 dimer), ActBcl2
(Activator-Bcl2 dimer), Ena (Enabler), EnaBcl2 (Enabler-Bcl2 dimer), MAC (Bax/Bak pore), W (null).
doi:10.1371/journal.pone.0001469.t001
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Table 2. Ordinary differential equations (ODEs) of the Direct
Model II.
......................................................................
d[InBax]/dt=JInBax2J12J9
d[AcBax]/dt=JAcBax+J12J22J42J5+J82J922?J10
d[Bcl2]/dt=JBcl22J22J32J6
d[Act]/dt=JAct2J12J3+J4+J7
d[ActBcl2]/dt=JActBcl2+J32J42J7
d[AcBaxBcl2]/dt=JAcBaxBcl2+J2+J42J8
d[Ena]/dt=JEna2J62J72J8
d[EnaBcl2]/dt=JEnaBcl2+J6+J7+J8
d[MAC]/dt=JMAC+J9+J10
With
JInBax=p12u1?[InBax] J1=k1?[InBax]?[Act]
JAcBax=2u2[AcBax] J2=k2?[AcBax]?[Bcl2]2k3?[AcBaxBcl2]
JAct=p22u3?[Act] J3=k4?[Act]?[Bcl2]2k5?[ActBcl2]
JBcl2=p32u4?[Bcl2] J4=k6?[AcBax]?[ActBcl2]2k7?[AcBaxBcl2]?[Act]
JActBcl2=2u5?[ActBcl2] J5=k8?[AcBax]
JAcBaxBcl2=2u6?[AcBaxBcl2] J6=k9?[Ena]?[Bcl2]2k10?[EnaBcl2]
JEna=p42u7?[Ena] J7=k11?[Ena]?[ActBcl2]2k12?[Act]?[EnaBcl2]
JEnaBcl2=2u8?[EnaBcl2] J8=k13?[Ena]?[AcBaxBcl2]2k14?[AcBax]?[EnaBcl2]
JMAC=2u9?[MAC] J9=k15?[InBax]?[AcBax]
J10=k16?[AcBax]
22k17?[MAC]
doi:10.1371/journal.pone.0001469.t002
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Bistable Bcl2 Apoptotic Switch
PLoS ONE | www.plosone.org 3 January 2008 | Issue 1 | e1469interactionsofBcl-2familyproteins.FromFig.2Awecanseethatno
bistable behavior emerges from the Direct Model (Fig. 1A).
However, Direct Model I (Fig. 1C), in which Bcl2 can also bind to
activated Bax/Bak (AcBax), shows desired bistable behavior of Bax
activation (Fig. 2B). This model exhibits three steady states, two
stable (solid lines) and one unstable (dashed lines). The two saddle-
node bifurcation points SN1 (0.0050) and SN2 (0.0061) enclose a
bistable region(enclosedby2verticaldashedlines).Starting fromthe
resting state, the system retains low level of Bax activation for
increasing stimuli, until a threshold is reached (SN2), whereby the
level of activated Bax/Bak switches (AcBax) to the higher stable state
in an all-or-none fashion. The system remains at this higher state
even if the stimulus is removed (between SN1 and SN2). Only when
the stimulus passes another threshold (SN1) can the system return to
its resting state. The level of monomer Bcl2 shows the opposite
pattern as AcBax. This is a typical toggle-switch governed by the
production rate of Activator. Parameters including the production
and degradation rates of other proteins can also give bifurcation
diagrams. For instance, bistability has been found when we use
degradation rate of AcBax as the apoptotic stimuli (Supplementary
materials, Fig. S1). Here for simplicity, we just used the production
rate of Activator to represent the apoptotic stimuli, and show the
bistability originated from interactions of Bcl-2 family proteins.
We next focused on the mechanism that leads to bistability of
Bax activation. It is apparent that the inhibition of Bcl2 brings
about ‘inhibitor ultrasensitivity’. That means the adding Activator
is first inhibited till their amount exceed the inhibition effect of
Bcl2. Also, we suggested that the interactions between AcBax and
Bcl2 can form a positive (double negative) feedback. AcBax can
bind Bcl2, and thereby sequesters Bcl2 away from the Activator.
Table 3. Parameters of the Direct Model II.
a
..................................................................................................................................................
Parameters Description Value
b Ref. and comment
[InBax]0 Initial concentration of InBax 60 Same as in [14]
[Act]0 Initial concentration of Act 1 Same as in [14]
[Bcl2]0 Initial concentration of Bcl2 30 Same as in [14]
[Ena]0 Initial concentration of Ena 1 Similar as in [14]
p1 Production rate of InBax 0.06 Estimated from [14,33]
p2 Production rate of Act 0.001 Estimated from [14,33]
p3 Production rate of Bcl2 0.03 Estimated from [14,33]
p4 Production rate of Ena 0.001 Estimated from [14,33]
u1 Degradation rate of InBax 0.001 Similar as in [33]
u2 Degradation rate of AcBax 0.001 Same as u1
u3 Degradation rate of Act 0.001 Same as u1
u4 Degradation rate of Bcl2 0.001 Same as u1
u5 Degradation rate of Act-Bcl2 dimer 0.005 Similar as in [33]
u6 Degradation rate of Bax-Bcl2 dimer 0.005 Same as u5
u7 Degradation rate of Ena 0.001 Same as u1
u8 Degradation rate of Ena-Bcl2 dimer 0.005 Same as u5
u9 Degradation rate of Bax oligomer (MAC) 0.0005 Estimated
k1 Act-mediated Activation of Bax 0.0005 Similar as in [14,33]
k2 Dimerization between AcBax and Bcl2 0.005 Similar as in [23]
k3 Dissociation of Bax-Bcl2 dimer 0.001 Same as in [14]
k4 Dimerization between Act and Bcl2 0.001 Similar as in [14,23]
k5 Dissociation of Act-Bcl2 dimer 0.001 Same as k3
k6 AcBax displace Act from Act-Bcl2 dimer 0.005 Same as k2
k7 Act displace AcBax from Bax-Bcl2 dimer 0.001 Same as k4
k8 Bax/Bak inactivation 0.001 Same as in [14]
k9 Dimerization between Ena and Bcl2 0.0001 Similar as in [14,23]
k10 Dissociation of Ena-Bcl2 dimer 0.001 Same as k3
k11 Ena displace Act from Act-Bcl2 dimer 0.0001 Same as k9
k12 Act displace Ena from Ena-Bcl2 dimer 0.001 Same as k4
k13 Ena displace AcBax from Bax-Bcl2 dimer 0.0001 Same as k9
k14 AcBax displace Ena from Ena-Bcl2 dimer 0.005 Same as k2
k15 Bax Auto-activation & dimerization 0.0002 estimated from k1
k16 Homo-dimerization of AcBax 0.0002 Same as k15
k17 Dissociation of Bax homo-dimer 0.02 Similar as in [40]
aTo get the original Direct Model, k2, k6, k14, k15 are set to be zero. In the Direct Model I, k15 is set to be zero.
bUnits: The total amounts of different species are expressed in units of nanomolar. The first and second rate constants are expressed in units of second
21 and
nanomolar
21second
21, respectively. The production rate constants are expressed in unit of nanomolar/s.
doi:10.1371/journal.pone.0001469.t003
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Bistable Bcl2 Apoptotic Switch
PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1469Thus more Bax can be activated. It is well known that positive
feedback incorporated with non-linear elements can lead to
bistability [24]. Here we can see that Bcl2, the anti-apoptotics play
a pivotal role in eliciting bistable behavior in the Bcl-2 network.
Bax Auto-activation as a Positive Feedback Enforces
the Bistability
Direct Model II (Fig. 1D) which is a more detailed network
involving Bax auto-activation also shows bistability (Fig. 3). It
displays lower threshold of Bax activation and larger bistable
domain than Direct Model I, which indicates that Bax auto-
activation establishes a strong positive feedback loop which
effectively enhances the bistable behavior. We can see that the
bistable region is extended, and shifted from [0.0050, 0.0061] to
[0.0019, 0.0052], compared to Direct Model I (Fig. 2B). The level
of ‘on state’ of AcBax is also lifted higher in contrast to Direct
Model I.
Bax auto-activation can also enforce model’s robustness of the
bistability. Here, we used a Monte Carlo based method to evaluate
the robustness of bistable behavior of the Bcl-2 network to
parameter variations. Latin Hypercube Sampling is used to
generate 2000 random sets of all the parameters of the model
with the variation of 40% (+/220%) relative to the reference
parameter values. From Fig. 4 (A and B, no Fix), we can see that
above 20% of the total 2000 parameter sets for each models
exhibit a bistable behavior in bistable regions ( [0.0050, 0.0061] of
Direct Model I and [0.0019, 0.0052] of Direct Model II). These
results indicate that the interactions of the Bcl-2 network can
generate a good switch to control cell death in a certain window of
parameter variations. In addition, when Bax auto-activation is
involved (Direct Model II), the highest percentage of bistability is
almost twice as the one in Direct Model I. The bistable range in
respect to production rate of Activator is also broadened and
moves to the left side of X-axis, which indicates that this positive
feedback loop could significantly enhance the robustness of model
system as well as the sensitivity in the face of apoptotic stimuli. In
addition, we found a remarkable degree of robustness when the
production rates of Bcl-2 family members are fixed in our model
(Fig. 4, Fix). In the expected bistable region, higher percentages of
bistability of both Models are reached. It indicates that the
regulation of Bcl-2 family proteins’ productions may play a key
role in determining the bistable behavior of the system.
From the bifurcation analysis of these models, we demonstrate
the potential molecular mechanism of the bistability arising from
hierarchic interactions of the Bcl-2 network. A positive (double
negative) feedback formed by activated Bax-Bcl-2 interactions
could be an internal reason of the emergence of this bio-switch.
Another possible positive feedback loop describing Bax auto-
activation can enforce such behavior and make the bistable range
wider and more robust with respect to parameter variations.
Influences of the Intrinsic Noise on the Bcl-2
Apoptotic Switch
Most bistable models only maintain their switch-like behavior in a
limited parameter range. These systems can hardly be considered
‘biologically bistable’ as they may not behave in a bistable manner
in the face of biological uncertainties, such as intrinsic noise and
parameter variations [25,26]. We have examined the influence of
parameter variations on the Bcl-2 apoptotic switch and have
Figure 2. Steady states of Activated Bax/Bak (AcBax) and Anti-apoptotics (Bcl2) as a function of the production rate of Activator (Act). (A) The
Direct Model. (B) The Direct Model I. The bistable region is enclosed by 2 vertical dashed lines.
doi:10.1371/journal.pone.0001469.g002
Figure 3. Bifurcation diagram of the Direct Model II. Steady states of
Activated Bax/Bak (AcBax) and Anti-apoptotics (Bcl2) are plotted as a
function of the production rate of Activator (Act). The bistable region is
enclosed by 2 vertical dashed lines.
doi:10.1371/journal.pone.0001469.g003
Bistable Bcl2 Apoptotic Switch
PLoS ONE | www.plosone.org 5 January 2008 | Issue 1 | e1469proved Bax auto-activation can improve the model’s robustness of
the bistability with respect to parameter variations. Here, we
continue to investigate the effect of noise on the bistable Bcl-2
apoptotic switch by performing stochastic modeling of the Direct
Model II. Actually, the effect of noise on bistable behaviors has
already been discussed elsewhere [26]. Our major focus in this
paper is not the general effect of noise on bistability but the
mechanisms of bistability embedded in the Bcl-2 network. And as
a specific example showing the influences of intrinsic noise on
bistable systems, we successfully modeled how intrinsic noise can
change ultrasensitive Bax activation switches into gradual
responses in cell populations and how bimodal Bax activation
distributions in cell populations are generated.
The time course of Bax activation in response to stimuli is
simulated and the results indicate that the Bax activation switch is
a robust bistable system since noise-induced transitions are rare
unless the stimulus is very near the bifurcation point (Supplemen-
tary Materials, Fig. S2). Eissing et al. presented a similar result in
their robustness analysis of two apoptosis models [27]. Here, we
also investigated the effects of noise on the dynamic behaviors of
Bax activation. Fig. 5 shows examples of stochastic simulations
with an initial activator number of 8 nM (estimated as 4800
Molecule per cell, here estimating a cell volume of 1 picoliter
results that 1 nM<600 molecules per cell) and a production rate of
Activator p2=3.14 Molecule/s per cell (estimated as 0.0052 nM/
s). Red curve demonstrates the time course of Bax activation by
deterministic model and blue curves are stochastic results. Both
red and blue curves are ‘S-shape’, showing prominent switch-like
behavior. Interestingly, intrinsic noise seems mainly to lead
different time-delays of the transition from low activated state to
high activated state of Bax compared to ‘standard form’ (red
curve). Thus the result of averaging the sample paths (dashed
curve) is no longer ‘S-shape like’ but gradual. Most experimental
studies on Bax/Bak activation and oligomerization have been
performed using cell populations (e.g. Western Blotting) where
graded but not all-or-none behaviors are often observed [28,29].
Those simulations give a plausible explanation that how the ‘all-
or-none’ bistable behavior of single cell converts to observed
gradual behavior of population data under noisy conditions.
Now experimental data based on single cell monitoring
techniques to confirm the Bax-activation switch proposed in our
models are still lacking. One alternative is to examine whether a
population of cells undergoing apoptosis can exhibit bimodal
population distributions in Bax activation. Recently, a series of
flow-cytometry experiments have detected a bifurcation of Bax
activation into two states [30,31]. Similar results have also been
Figure 4. Parametric robustness of bistability. (A) The Direct Model I. (B) The Direct Model II. For any given production rate of Activator
(0.001,0.010), the percentage of parameter sets that exhibits bistability are plotted. No Fix: All of the parameters are varied +/220% from its default
value. Fix: The production rates of Bcl-2 family proteins (p1,p4) are fixed while all other parameters are varied +/220% from its default value for each
sample run.
doi:10.1371/journal.pone.0001469.g004
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PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1469Figure 5. Time-series of the Activated Bax/Bak (AcBax) by deterministic and stochastic simulations. The production rate of Activator is set to be
p2=0.0052 nM/s (estimated as 3.14 Molecule/s per cell). The initial concentration of Act is adopted as [Act]0=8 nM (estimated as 4800 Molecule per
cell). The red line is the result from a deterministic simulation and the green line is the average of 10000 stochastic simulations. 10 of the stochastic
simulation time-series are plotted as blue lines.
doi:10.1371/journal.pone.0001469.g005
Figure 6. Probability distributions of Activated Bax/Bak (AcBax) molecule per cell as a function of time. Histograms are generated from the
stochastic simulations at times 2000, 4000, 6000, 8000s of 10000 independent runs.
doi:10.1371/journal.pone.0001469.g006
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evidence to support our hypothesis that there exists a Bax/Bak-
activation switch. The two independent positive feedbacks
embedded in the Bcl-2 interaction network can provide a plausible
explanation for this switch. Here we used ensemble modeling to
prove how bimodal distribution can be generated from the switch
under intrinsic noise. The sample paths (totally 10000 independent
simulations) are used to produce histograms of the activated Bax at
several different times (Fig. 6). Our modeling results show the
desired transient binary response of Bax activation, which is
consistent with these experimental observations.
DISCUSSION
Previously, most models explaining bistable behavior of apoptosis
regard events downstream of mitochondria, such as caspases
activation, as necessary parts in bistability [33–35]. However
growing evidence has supported the importance of a so called ‘Bcl-
2 apoptotic switch’ upstream of mitochondria [9]. The evidence
include: (1) MOMP itself is all-or-none, irreversible [5], (2)
MOMP can conduct apoptosis even its downstream events such as
caspase activation are inhibited [36], (3) MOMP is mainly
regulated by Bcl-2 family proteins [7], and (4) unrestrained Bax/
Bak activation can act as the decision point to apoptosis [37].
Nevertheless, the molecular mechanism of the Bcl-2 apoptotic
switch remains in hot debate. Multiple models can be cataloged
into two distinct ideas, namely the Direct Activation Model and
the Indirect Activation Model [10,13]. Despite the contradicting
experimental evidences, mathematical modeling provides a useful
strategy to study the dynamical property and plausibility of these
models.
In our former work we have identified a Direct Activation
Model as a more plausible explanation for the switch-like behavior
as well as three other salient features [14]. Also, in another paper
we proposed a bistable model of Bax-activation by using both
deterministic and stochastic modeling [23]. However it is still
worthwhile to study whether bistability can originate in a model
embracing emerging experimental findings as well as protein
synthesis and degradation, which have been reported of great
importance in apoptosis regulation (but not considered in our
former modeling studies). In this paper we included updating
knowledge into our former selected Direct Activation Model for
the Bcl-2 apoptotic switch. Our modeling results successfully
reveal that two positive feedbacks embedded in the Bcl-2 network
can lead bistability and give a plausible explanation for the Bcl-2
apoptotic switch. We also showed that this switch can lead
bimodal Bax-activation distribution of cell population by stochastic
modeling, which is well in accord with recent experimental
findings. Our analysis provides solid evidence that the Direct
Activation Model is a plausible explanation for both Bax activation
switch and apoptosis decision.
Although we believe Bcl-2 family proteins constitute a most
important checkpoint upon mitochondria, it should be noted that
various bistable switches downstream or independent of mito-
chondria have also been elucidated [33–35]. It would be quite
interesting to study the cooperation of these switches when more
numerical data is attainable to construct models of complete
apoptosis network. Also, comparing these mechanisms can lead to
interesting findings. It is surprising to find that the mechanism of
bistability in the Bcl-2 apoptotic switch is quite similar to that
described by Legewie et al. for a caspase activation switch [34]. In
their model, activated Caspase3 can bind XIAP, and thereby
sequesters XIAP away from activated Caspase9, which in turn
activate more Caspase3. Quite similar to Bcl-2, XIAP establish a
positive (double negative) feedback which brings bistability. In
addition, there is also an independent positive feedback (Caspase3-
mediated feedback cleavage of Caspase9) which enforces the
bistability. Thus, we can conclude that there should be a general
strategy adopted by cells in generating signaling switches: A weak
non-liner positive feedback which generates bistability combined
with a strong positive feedback which enforces the bistability.
Another conclusion is that the Direct Activation Model is more
plausible than the Indirect Activation Model we describe before.
Growing experimental evidence not only criticizes the basis for the
Indirect Activation Model, but also proves that the Direct
Activation Model can show bistability, a kind of switch. Also, we
revealed that the bistability of the Direct Model is robust enough
to withstand parameter variations as well as intrinsic noise. In
contrast, the Indirect Model lacks both inhibition insensitivity
ultrasensitivity and positive feedbacks which may contribute to
switch-like responses.
The imbalance of Bcl-2 family protein expressions can cause a
variety of diseases (e.g. cancers), which further proves the crucial
therapeutic role of Bcl-2 apoptotic switch. Our studies here also
provide insights into pharmacological manipulation of Bcl-2 family
members as cancer therapies. Here the central issue is how to
switch the bistable system of Bcl-2 network to on-state and kill
tumor cells by manipulating Bcl-2 family proteins. Several BH-3
mimetics have already been designed to sequester anti-apoptotics
and trigger apoptosis in tumor cells [38,39]. We can expect in the
future they will be used as a part of normal clinical practice,
combining with more precise mathematical modeling which will
help to identify specific windows for drug therapies.
In all, through extending the models of Bcl-2 apoptotic switch
based on updating experimental findings, we successfully identified
two independent positive feedbacks which contribute to the switch
mechanism in Bax-activation.
SUPPORTING INFORMATION
Figure S1 Bifurcation diagram of Bax activation as a function of
the degradation rate of Bax. Steady states of Activated Bax/Bak
(AcBax) are plotted as a function of the degradation rate of Bax.
Found at: doi:10.1371/journal.pone.0001469.s001 (0.02 MB
PDF)
Figure S2 Influences of the intrinsic noise on the transition of
the Bcl-2 apoptotic switch. Possibilities of transition from resting
state to on state of Bax activation by changing production rate of
Activator under deterministic simulation (solid line) and stochastic
simulation (dashed line). For each given value of production rate of
Activator, 10000 independent runs are taken for stochastic
simulation.
Found at: doi:10.1371/journal.pone.0001469.s002 (0.02 MB
PDF)
Table S1 Reaction scheme of the Direct Model.
Found at: doi:10.1371/journal.pone.0001469.s003 (0.06 MB
PDF)
Table S2 Ordinary Differential Equations of the Direct Model.
Found at: doi:10.1371/journal.pone.0001469.s004 (0.04 MB
PDF)
Table S3 Reaction scheme of the Direct Model I.
Found at: doi:10.1371/journal.pone.0001469.s005 (0.06 MB
PDF)
Table S4 Ordinary Differential Equations of the Direct Model I.
Found at: doi:10.1371/journal.pone.0001469.s006 (0.04 MB
PDF)
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